LEADER 03511nam 2200589 a 450 001 9910877897903321 005 20200520144314.0 010 $a1-283-14057-8 010 $a9786613140579 010 $a3-527-63318-9 010 $a3-527-63316-2 010 $a3-527-63317-0 035 $a(CKB)2670000000060524 035 $a(EBL)645017 035 $a(SSID)ssj0000472391 035 $a(PQKBManifestationID)12168033 035 $a(PQKBTitleCode)TC0000472391 035 $a(PQKBWorkID)10434202 035 $a(PQKB)10620790 035 $a(MiAaPQ)EBC645017 035 $a(OCoLC)714798782 035 $a(EXLCZ)992670000000060524 100 $a20110114d2011 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aProdrugs and targeted delivery $etowards better ADME properties /$fedited by Jarkko Rautio 210 $aWeinheim, Germany $cWiley-VCH$d2011 215 $a1 online resource (522 p.) 225 1 $aMethods and principles in medicinal chemistry ;$vv. 47 300 $aDescription based upon print version of record. 311 $a3-527-32603-0 320 $aIncludes bibliographical references and index. 327 $aProdrugs and Targeted Delivery: Towards Better ADME Properties; Contents; List of Contributors; Preface; A Personal Foreword; Part One: Prodrug Design and Intellectual Property; 1 Prodrug Strategies in Drug Design; 2 The Molecular Design of Prodrugs by Functional Group; 3 Intellectual Property Primer on Pharmaceutical Patents with a Special Emphasis on Prodrugs and Metabolites; Part Two: Prodrugs Addressing ADMET Issues; 4 Increasing Lipophilicity for Oral Drug Delivery; 5 Modulating Solubility Through Prodrugs for Oral and IV Drug Delivery 327 $a6 Prodrugs Designed to Target Transporters for Oral Drug Delivery7 Topical and Transdermal Delivery Using Prodrugs: Mechanism of Enhancement; 8 Ocular Delivery Using Prodrugs; 9 Reducing Presystemic Drug Metabolism; 10 Enzyme-Activated Prodrug Strategies for Site-Selective Drug Delivery; 11 Prodrug Approaches for Central Nervous System Delivery; 12 Directed Enzyme Prodrug Therapies; Part Three: Codrugs and Soft Drugs; 13 Improving the Use of Drug Combinations Through the Codrug Approach; 14 Soft Drugs; Part Four: Preclinical and Clinical Consideration for Prodrugs 327 $a15 Pharmacokinetic and Biopharmaceutical Considerations in Prodrug Discovery and Development16 The Impact of Pharmacogenetics on the Clinical Outcomes of Prodrugs; Index 330 $aThis topical reference and handbook addresses the chemistry, pharmacology, toxicology and the patentability of prodrugs, perfectly mirroring the integrated approach prevalent in today's drug design. It summarizes current experiences and strategies for the rational design of prodrugs, beginning at the early stages of the development process, as well as discussing organ- and site-selective prodrugs. Every company employing medicinal chemists will be interested in this practice-oriented overview of a key strategy in modern drug discovery and development. 410 0$aMethods and principles in medicinal chemistry ;$vv. 47. 606 $aProdrugs 615 0$aProdrugs. 676 $a615.19 676 $a615.191 701 $aRautio$b Jarkko$01346070 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910877897903321 996 $aProdrugs and targeted delivery$94199774 997 $aUNINA